Skip to main content
Premium Trial:

Request an Annual Quote

Compugen, Premier Biosoft

Premium
Compugen this week introduced the Viral Peptides Discovery Platform for the identification of peptides from viral genomes for potential therapeutic use against inflammatory and immune-related diseases.
 
The company said the platform has been validated and led to the discovery of two novel viral peptides that have demonstrated the ability to suppress inflammatory response in in vitro studies.
 
Using algorithms and in silico tools that predict a large number of potential natural peptides produced by viruses, the platform chooses those peptides that show potential anti-inflammatory activities.
 

 
Premier Biosoft this week launched SimGlycan version 2.6.
 
The MS/MS data analysis software now annotates mass spectra, showing the loss of successive monosaccharides with each peak, “enabling better glycan visualization and outputting publication quality graphics of the results,” the company said in a statement.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.